Last reviewed · How we verify
NCT06085677: GEM
The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
trial in Stomach Neoplasm in 600 participants. Status unknown.
2 September 2024
Quick facts
| Lead sponsor | Imperial College London |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 4 November 2023 |
| Primary completion | 2 September 2024 |
| Estimated completion | 2 September 2024 |
Conditions studied
- Stomach Neoplasm — all drugs for Stomach Neoplasm →
- Chronic Atrophic Gastritis — all drugs for Chronic Atrophic Gastritis →
- Intestinal Metaplasia — all drugs for Intestinal Metaplasia →
Sponsor
Imperial College London
Who can join
Adults 18 to 80, any sex, with Stomach Neoplasm or Chronic Atrophic Gastritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of the study is to understand whether blood levels of hormones produced or metabolized in the stomach reflect the health of the stomach lining. Specifically the study will determine whether the concentration of ghrelin, gastrin, pepsinogens and vitamin B12 reflect the condition of the stomach lining. Hormone concentrations for people with normal/mild gastritis will be compared to people with long-term inflammation of the stomach (chronic atrophic gastritis), and people with pre-cancerous cellular changes (intestinal metaplasia).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06085677
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stomach Neoplasm
Currently open trials in the same condition.
- NCT06732856 — A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locall · Phase 1, PHASE2 · recruiting
- NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
- NCT06923449 — Gastric Cancer' Textbook Oncological Outcome and Tumor Board Performance · recruiting
- NCT05180864 — Omentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer · NA · recruiting
- NCT05640609 — Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer · Phase 1, PHASE2 · recruiting
Other Imperial College London trials
Trials by the same sponsor.
- NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
- NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
- NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
- NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
- NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06085677 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imperial College London
- Last refreshed: 17 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06085677.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing